NL-OMON49089已完成4 期
A 2-year follow-up study to assess cognition and health-related quality of life in participants with highly-active relapsing multiple sclerosis, having participated in the CLARIFY MS trial - CLARIFY MS Extension
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Merck
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Participants having participated in the CLARIFY MS trial, who:
- •a. Have at least CLARIFY MS Baseline data on SDMT;
- •b. Received at least a single dose of cladribine tablets in the CLARIFY MS
- •c. Completed the Final Study Visit (M24) of the CLARIFY MS trial.
- •2. Capable of giving signed informed consent, which includes compliance with
- •the requirements and restrictions listed in the informed consent form (ICF) and
- •this protocol.
排除标准
- •1. Participant is considered by the Investigator and Sponsor, for any reason,
- •to be an unsuitable candidate for the study.
- •2. Participation in other studies/trials.
研究者
相似试验
进行中（未招募）
1 期
Cognition and HRQoL in adults with highly-active RMS in Year 3 and 4 after initial Mavenclad® doseHighly-active relapsing multiple sclerosisMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003874-30-ATMerck Healthcare KGaA380
进行中（未招募）
1 期
Cognition and HRQoL in adults with highly-active RMS in Year 3 and 4 after initial Mavenclad® doseHighly-active relapsing multiple sclerosisMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003874-30-HUMerck Healthcare KGaA320
进行中（未招募）
1 期
Cognition and HRQoL in adults with highly-active RMS in Year 3 and 4 after initial Mavenclad® doseHighly-active relapsing multiple sclerosisMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003874-30-DKMerck Healthcare KGaA380
进行中（未招募）
1 期
Cognition and HRQoL in adults with highly-active RMS in Year 3 and 4 after initial Mavenclad® doseHighly-active relapsing multiple sclerosisMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003874-30-CZMerck Healthcare KGaA380
进行中（未招募）
1 期
Cognition and HRQoL in adults with highly-active RMS in Year 3 and 4 after initial Mavenclad® doseEUCTR2020-003874-30-ITMERCK KGAA320